102 related articles for article (PubMed ID: 10100702)
1. Leukocyte O6-alkylguanine-DNA alkyltransferase from human donors is uniformly sensitive to O6-benzylguanine.
Gerson SL; Schupp J; Liu L; Pegg AE; Srinivasen S
Clin Cancer Res; 1999 Mar; 5(3):521-4. PubMed ID: 10100702
[TBL] [Abstract][Full Text] [Related]
2. Isolation of human O6-alkylguanine-DNA alkyltransferase mutants highly resistant to inactivation by O6-benzylguanine.
Xu-Welliver M; Kanugula S; Pegg AE
Cancer Res; 1998 May; 58(9):1936-45. PubMed ID: 9581836
[TBL] [Abstract][Full Text] [Related]
3. Alteration of the conserved residue tyrosine-158 to histidine renders human O6-alkylguanine-DNA alkyltransferase insensitive to the inhibitor O6-benzylguanine.
Xu-Welliver M; Leitão J; Kanugula S; Pegg AE
Cancer Res; 1999 Apr; 59(7):1514-9. PubMed ID: 10197622
[TBL] [Abstract][Full Text] [Related]
4. Protection of CHO cells by mutant forms of O6-alkylguanine-DNA alkyltransferase from killing by 1,3-bis-(2-chloroethyl)-1-nitrosourea (BCNU) plus O6-benzylguanine or O6-benzyl-8-oxoguanine.
Loktionova NA; Xu-Welliver M; Crone TM; Kanugula S; Pegg AE
Biochem Pharmacol; 1999 Jul; 58(2):237-44. PubMed ID: 10423163
[TBL] [Abstract][Full Text] [Related]
5. Role of codon 160 in the sensitivity of human O6-alkylguanine-DNA alkyltransferase to O6-benzylguanine.
Xu-Welliver M; Leitão J; Kanugula S; Meehan WJ; Pegg AE
Biochem Pharmacol; 1999 Oct; 58(8):1279-85. PubMed ID: 10487529
[TBL] [Abstract][Full Text] [Related]
6. Heterogeneity of O6-alkylguanine-DNA-alkyltransferase measured by flow cytometric analysis in blood and bone marrow mononuclear cells.
Liu L; Lee K; Schupp J; Koç ON; Gerson SL
Clin Cancer Res; 1998 Feb; 4(2):475-81. PubMed ID: 9516939
[TBL] [Abstract][Full Text] [Related]
7. Potentiation of BCNU anticancer activity by O6-benzylguanine: a study in vitro and in vivo.
Wan Y; Wu D; Gao H; Lu H
J Environ Pathol Toxicol Oncol; 2000; 19(1-2):69-75. PubMed ID: 10905510
[TBL] [Abstract][Full Text] [Related]
8. New cytotoxic agents for the treatment of metastatic malignant melanoma: temozolomide and related alkylating agents in combination with guanine analogues to abrogate drug resistance.
Spiro T; Liu L; Gerson S
Forum (Genova); 2000; 10(3):274-85. PubMed ID: 11007934
[TBL] [Abstract][Full Text] [Related]
9. Differential degradation rates of inactivated alkyltransferase in blood mononuclear cells and tumors of patients after treatment with O(6)-benzylguanine.
Liu L; Spiro TP; Qin X; Majka S; Haaga J; Schupp J; Willson JK; Gerson SL
Clin Cancer Res; 2001 Aug; 7(8):2318-24. PubMed ID: 11489807
[TBL] [Abstract][Full Text] [Related]
10. Inactivation of O6-alkylguanine-DNA alkyltransferase by 8-substituted O6-benzylguanine analogs in mice.
Ewesuedo RB; Wilson LR; Friedman HS; Moschel RC; Dolan ME
Cancer Chemother Pharmacol; 2001; 47(1):63-9. PubMed ID: 11221964
[TBL] [Abstract][Full Text] [Related]
11. Differential sensitivity of human and mouse alkyltransferase to O6-benzylguanine using a transgenic model.
Liu L; Lee K; Wasan E; Gerson SL
Cancer Res; 1996 Apr; 56(8):1880-5. PubMed ID: 8620508
[TBL] [Abstract][Full Text] [Related]
12. Point mutations in human O6-alkylguanine-DNA alkyltransferase prevent the sensitization by O6-benzylguanine to killing by N,N'-bis (2-chloroethyl)-N-nitrosourea.
Loktionova NA; Pegg AE
Cancer Res; 1996 Apr; 56(7):1578-83. PubMed ID: 8603405
[TBL] [Abstract][Full Text] [Related]
13. Mutations in human O6-alkylguanine-DNA alkyltransferase imparting resistance to O6-benzylguanine.
Crone TM; Goodtzova K; Edara S; Pegg AE
Cancer Res; 1994 Dec; 54(23):6221-7. PubMed ID: 7954470
[TBL] [Abstract][Full Text] [Related]
14. Lack of evidence for a polymorphism at codon 160 of human O6-alkylguanine-DNA alkyltransferase gene in normal tissue and cancer.
Wu MH; Lohrbach KE; Olopade OI; Kokkinakis DM; Friedman HS; Dolan ME
Clin Cancer Res; 1999 Jan; 5(1):209-13. PubMed ID: 9918221
[TBL] [Abstract][Full Text] [Related]
15. Depletion of O6-alkylguanine-DNA alkyltransferase by O6-benzylguanine in three-dimensional collagen cultures of normal human breast epithelial cells.
Hamdan MA; Guzman RC; Yang J; Beattie C; Mascharack P; Nandi S
Carcinogenesis; 1992 Oct; 13(10):1743-9. PubMed ID: 1423833
[TBL] [Abstract][Full Text] [Related]
16. Mismatch repair mutations override alkyltransferase in conferring resistance to temozolomide but not to 1,3-bis(2-chloroethyl)nitrosourea.
Liu L; Markowitz S; Gerson SL
Cancer Res; 1996 Dec; 56(23):5375-9. PubMed ID: 8968088
[TBL] [Abstract][Full Text] [Related]
17. Resistance of the human O6-alkylguanine-DNA alkyltransferase containing arginine at codon 160 to inactivation by O6-benzylguanine.
Edara S; Kanugula S; Goodtzova K; Pegg AE
Cancer Res; 1996 Dec; 56(24):5571-5. PubMed ID: 8971155
[TBL] [Abstract][Full Text] [Related]
18. Inactivation of O6-alkylguanine DNA alkyltransferase as a means to enhance chemotherapy.
Rabik CA; Njoku MC; Dolan ME
Cancer Treat Rev; 2006 Jun; 32(4):261-76. PubMed ID: 16698182
[TBL] [Abstract][Full Text] [Related]
19. 3-aminobenzamide and/or O6-benzylguanine evaluated as an adjuvant to temozolomide or BCNU treatment in cell lines of variable mismatch repair status and O6-alkylguanine-DNA alkyltransferase activity.
Wedge SR; Porteous JK; Newlands ES
Br J Cancer; 1996 Oct; 74(7):1030-6. PubMed ID: 8855970
[TBL] [Abstract][Full Text] [Related]
20. Determination of the optimal modulatory dose of O6-benzylguanine in patients with surgically resectable tumors.
Dolan ME; Posner M; Karrison T; Radosta J; Steinberg G; Bertucci D; Vujasin L; Ratain MJ
Clin Cancer Res; 2002 Aug; 8(8):2519-23. PubMed ID: 12171878
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
